These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37063482)

  • 1. Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles.
    Jo DH; Kaczmarek S; Shin O; Wang L; Cowan J; McComb S; Lee SH
    Mol Ther Methods Clin Dev; 2023 Jun; 29():173-184. PubMed ID: 37063482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
    Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
    Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
    Ureña-Bailén G; Dobrowolski JM; Hou Y; Dirlam A; Roig-Merino A; Schleicher S; Atar D; Seitz C; Feucht J; Antony JS; Mohammadian Gol T; Handgretinger R; Mezger M
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
    Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
    Huang RS; Lai MC; Lin S
    Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-free CRISPR knock-in of a chimeric antigen receptor into
    Shankar K; Zingler-Hoslet I; Shi L; Katta V; Russell BE; Tsai SQ; Capitini CM; Saha K
    bioRxiv; 2024 Feb; ():. PubMed ID: 38405747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
    Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
    J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro.
    Alishah K; Birtel M; Masoumi E; Jafarzadeh L; Mirzaee HR; Hadjati J; Voss RH; Diken M; Asad S
    J Transl Med; 2021 Nov; 19(1):482. PubMed ID: 34838059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. shp-2 gene knockout upregulates CAR-driven cytotoxicity of YT NK cells.
    Subrakova VG; Kulemzin SV; Belovezhets TN; Chikaev AN; Chikaev NA; Koval OA; Gorchakov AA; Taranin AV
    Vavilovskii Zhurnal Genet Selektsii; 2020 Feb; 24(1):80-86. PubMed ID: 33659784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR, CAR-T, and NK: Current applications and future perspectives.
    Khoshandam M; Soltaninejad H; Hamidieh AA; Hosseinkhani S
    Genes Dis; 2024 Jul; 11(4):101121. PubMed ID: 38545126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
    Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
    Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
    Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer cell engineering - a new hope for cancer immunotherapy.
    Lin CY; Gobius I; Souza-Fonseca-Guimaraes F
    Semin Hematol; 2020 Oct; 57(4):194-200. PubMed ID: 33256912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells.
    Mohammadian Gol T; Kim M; Sinn R; Ureña-Bailén G; Stegmeyer S; Gratz PG; Zahedipour F; Roig-Merino A; Antony JS; Mezger M
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
    Gurney M; Stikvoort A; Nolan E; Kirkham-McCarthy L; Khoruzhenko S; Shivakumar R; Zweegman S; Van de Donk NWCJ; Mutis T; Szegezdi E; Sarkar S; O'Dwyer M
    Haematologica; 2022 Feb; 107(2):437-445. PubMed ID: 33375774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering.
    Hamilton JR; Tsuchida CA; Nguyen DN; Shy BR; McGarrigle ER; Sandoval Espinoza CR; Carr D; Blaeschke F; Marson A; Doudna JA
    Cell Rep; 2021 Jun; 35(9):109207. PubMed ID: 34077734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.